SR1 Capital Management
OrganizationHeard in 1 episode across 1 show since Oct 2026
SR1 Capital Management is a biotechnology venture capital firm spun out of GSK in 2020 and focused on investing in and building life-science companies.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
Email alert
Email me when SR1 Capital Management comes up on a podcast
One email a week at most, with the new episodes that mention SR1 Capital Management. Free, no account needed, unsubscribe in one click.
What experts have said about SR1 Capital Management
3 statements · 3 positive
SR1 generated strong financial returns during its GSK corporate-venture period.
“The fund did incredibly well from a financial return standpoint.”
Open the episode · AI, China, And Biotech Investing With SR One's Simeon George, M.D.Listen at 6:18
SR1 manages more than $2 billion across multiple funds.
“we now manage over 2 billion across multiple funds”
Open the episode · AI, China, And Biotech Investing With SR One's Simeon George, M.D.Listen at 9:03
SR1 invests in platforms only when focused on medicines addressing specific unmet needs.
“the platform has to be focused around a medicine in a particular unmet need that we believe is going to create significant value if we can hit that target product profile”
Open the episode · AI, China, And Biotech Investing With SR One's Simeon George, M.D.Listen at 14:16
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring SR1 Capital Management, newest first
